{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:34:18Z","timestamp":1789583658076,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.phrs.2020.104694","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T17:20:57Z","timestamp":1581528057000},"page":"104694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence"],"prefix":"10.1016","volume":"155","author":[{"given":"Alberto","family":"Aimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Cerbai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bartolucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Barison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppa","family":"Lo Surdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Biagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Passino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.104694_bib0005","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ejhf.1406","article-title":"Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.phrs.2020.104694_bib0010","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2020.104694_bib0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2020.104694_bib0020","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(11)60546-1","article-title":"Pirfenidone for idiopathic pulmonary fibrosis","volume":"377","author":"Bouros","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2020.104694_bib0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.phrs.2020.104694_bib0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Resp. Med."},{"key":"10.1016\/j.phrs.2020.104694_bib0035","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/ejhf.1286","article-title":"Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis","volume":"20","author":"Graziani","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.phrs.2020.104694_bib0040","unstructured":"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/pirfenidone."},{"key":"10.1016\/j.phrs.2020.104694_bib0045","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/022535Orig1s000PharmR.pdf."},{"key":"10.1016\/j.phrs.2020.104694_bib0050","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208780Orig1s000ClinPharmR.pdf."},{"key":"10.1016\/j.phrs.2020.104694_bib0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/bdd.1932","article-title":"Pharmacokinetic evaluation of tissue distribution of pirfenidone and its metabolites for idiopathic pulmonary fibrosis therapy","volume":"36","author":"Togami","year":"2015","journal-title":"Biopharm. Drug Disp."},{"key":"10.1016\/j.phrs.2020.104694_bib0060","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0091270007304104","article-title":"Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers","volume":"47","author":"Shi","year":"2007","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.phrs.2020.104694_bib0065","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pupt.2009.03.003","article-title":"Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults","volume":"22","author":"Rubino","year":"2009","journal-title":"Pulm. Pharm. Ther."},{"key":"10.1016\/j.phrs.2020.104694_bib0070","first-page":"4","article-title":"Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study","author":"Cottin","year":"2018","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.phrs.2020.104694_bib0075","first-page":"19","article-title":"Targeting TGF-\u03b2 signaling in kidney fibrosis","author":"Isaka","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2020.104694_bib0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-230X-14-131","article-title":"Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C","volume":"14","author":"Flores-Contreras","year":"2014","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.phrs.2020.104694_bib0085","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86017","article-title":"The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis","volume":"1","author":"Ahidjo","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2020.104694_bib0090","first-page":"26","article-title":"Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis","author":"Lancaster","year":"2017","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.phrs.2020.104694_bib0095","doi-asserted-by":"crossref","first-page":"40523","DOI":"10.1038\/srep40523","article-title":"Pirfenidone controls the feedback loop of the AT1R\/p38 MAPK\/renin-angiotensin system axis by regulating liver X receptor-alpha in myocardial infarction-induced cardiac fibrosis","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2020.104694_bib0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41232-017-0046-5","article-title":"Pathophysiology and therapeutic potential of cardiac fibrosis","volume":"37","author":"Hara","year":"2017","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.phrs.2020.104694_bib0105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2466-12-24","article-title":"Pirfenidone inhibits TGF-beta1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells","volume":"12","author":"Hisatomi","year":"2012","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.phrs.2020.104694_bib0110","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/labinvest.3700669","article-title":"Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations","volume":"87","author":"Prud\u2019homme","year":"2007","journal-title":"Lab. Invest."},{"key":"10.1016\/j.phrs.2020.104694_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028134","article-title":"In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion","volume":"6","author":"Shi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104694_bib0120","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ccm.2004.04.003","article-title":"Idiopathic pulmonary fibrosis: new insights into pathogenesis","volume":"25","author":"Noble","year":"2004","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.phrs.2020.104694_bib0125","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1378\/chest.09-0510","article-title":"New mechanisms of pulmonary fibrosis","volume":"136","author":"Strieter","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.phrs.2020.104694_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000351179","article-title":"Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation","volume":"126","author":"Wang","year":"2013","journal-title":"Cardiology"},{"key":"10.1016\/j.phrs.2020.104694_bib0135","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/TP.0b013e3181ae3392","article-title":"Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses","volume":"88","author":"Visner","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.phrs.2020.104694_bib0140","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2017-01-758854","article-title":"Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-beta production","volume":"129","author":"Du","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2020.104694_bib0145","article-title":"Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5\/6 nephrectomized rats","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104694_bib0150","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/cvr\/cvs248","article-title":"Chronic potentiation of cardiac L-type Ca(2+) channels by pirfenidone","volume":"96","author":"Ramos-Mondragon","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2020.104694_bib0155","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.bjp.0704539","article-title":"Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats","volume":"135","author":"Mirkovic","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104694_bib0160","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/hr.2011.139","article-title":"The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice","volume":"35","author":"Yamazaki","year":"2012","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.phrs.2020.104694_bib0165","doi-asserted-by":"crossref","first-page":"H512","DOI":"10.1152\/ajpheart.00137.2015","article-title":"Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts","volume":"309","author":"Yamagami","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2020.104694_bib0170","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.bjp.0704131","article-title":"Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats","volume":"133","author":"Miric","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104694_bib0175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00280-003-0703-z","article-title":"Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats","volume":"53","author":"Giri","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104694_bib0180","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.106.624320","article-title":"Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure","volume":"114","author":"Lee","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2020.104694_bib0185","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mus.20590","article-title":"Long-term administration of pirfenidone improves cardiac function in mdx mice","volume":"34","author":"Van Erp","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.phrs.2020.104694_bib0190","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.hrthm.2010.04.030","article-title":"Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias","volume":"7","author":"Nguyen","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.phrs.2020.104694_bib0195","first-page":"3","article-title":"Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury","author":"Adamo","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2020.104694_bib0200","unstructured":"http:\/\/www.atsjournals.org\/doi\/abs\/10.1164\/ajrccm-nference.2016.193.1_MeetingAbstracts.A498."},{"key":"10.1016\/j.phrs.2020.104694_bib0205","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","article-title":"Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness","volume":"72","author":"Jia","year":"2018","journal-title":"Hypertension"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819327574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819327574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:05:31Z","timestamp":1760911531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819327574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":41,"alternative-id":["S1043661819327574"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104694","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104694"}}